Grant David G, Hinni Michael L, Salassa John R, Perry William C, Hayden Richard E, Casler John D
Department of Otolaryngology-Head & Neck Surgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Arch Otolaryngol Head Neck Surg. 2009 Dec;135(12):1225-30. doi: 10.1001/archoto.2009.185.
To demonstrate the role of transoral laser microsurgery (TLM) in the treatment of oropharyngeal cancer.
A 2-center retrospective case series analysis.
Two tertiary care medical centers.
The study population comprised 69 patients with previously untreated select T1 to T3, N0 to N2 squamous cell carcinoma of the oropharynx, of whom 44 (74%) had no indication for adjuvant RT and 25 (36%) had an indication for adjuvant RT to the neck alone but declined radiotherapy. The primary tumor sites were the tonsil (n = 28 [41%]), tongue base (n = 28 [41%]), pharyngeal wall (n = 8 [12%]), soft palate (n = 4 [6%]), and vallecula (n = 1 [1%]).
Transoral laser microsurgery in 69 patients, with neck dissection in 59 patients (83%).
Complications, local and regional control, overall and disease-specific survival, swallow function, and feeding tube dependence.
Over the mean follow-up period of 44 months, 66 of 69 patients had no disease recurrence at the primary site. The 5-year local control estimate was 94%. The mean duration of hospitalization was 3 days. There were no major complications relating to TLM. No patient required a permanent feeding or tracheostomy tube. For stage I, II, and III disease, the 5-year Kaplan-Meier estimates of locoregional control were 90%, 73%, and 70%, respectively. The 5-year overall survival estimate was 86%.
Transoral laser microsurgery alone with or without neck dissection is an effective approach for select T1 to T3, N0, or N1 oropharyngeal cancer. Low levels of morbidity, short treatment duration, and excellent disease control make it an attractive therapeutic strategy. The treatment option of endoscopic-assisted laser microsurgery should be discussed by the multidisciplinary team for patients presenting with tumors suitable for this approach.
探讨经口激光显微手术(TLM)在口咽癌治疗中的作用。
一项双中心回顾性病例系列分析。
两家三级医疗中心。
研究人群包括69例未经治疗的口咽鳞状细胞癌患者,肿瘤分期为T1至T3、N0至N2,其中44例(74%)无辅助放疗指征,25例(36%)仅颈部有辅助放疗指征但拒绝放疗。原发肿瘤部位为扁桃体(n = 28 [41%])、舌根(n = 28 [41%])、咽壁(n = 8 [12%])、软腭(n = 4 [6%])和会厌谷(n = 1 [1%])。
69例患者接受经口激光显微手术,59例(83%)患者接受颈部清扫术。
并发症、局部和区域控制、总生存率和疾病特异性生存率、吞咽功能及胃管依赖情况。
在平均44个月的随访期内,69例患者中有66例原发部位无疾病复发。5年局部控制率估计为94%。平均住院时间为3天。未发生与经口激光显微手术相关的严重并发症。无患者需要长期留置胃管或气管造瘘管。对于Ⅰ期、Ⅱ期和Ⅲ期疾病,5年局部区域控制的Kaplan-Meier估计值分别为90%、73%和70%。5年总生存率估计为86%。
单独进行经口激光显微手术,无论是否联合颈部清扫术,对于选择合适的T1至T3、N0或N1期口咽癌都是一种有效的治疗方法。低发病率、短治疗时间和良好的疾病控制使其成为一种有吸引力的治疗策略。对于适合这种方法的肿瘤患者,多学科团队应讨论内镜辅助激光显微手术的治疗选择。